378 related articles for article (PubMed ID: 30871527)
1. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
2. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of
Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
[TBL] [Abstract][Full Text] [Related]
7. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
9. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.
Kristensen LS; Asmar F; Dimopoulos K; Nygaard MK; Aslan D; Hansen JW; Ralfkiaer E; Grønbæk K
Oncotarget; 2014 Oct; 5(20):9798-810. PubMed ID: 25229255
[TBL] [Abstract][Full Text] [Related]
11. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Li Y; Gordon MW; Xu-Monette ZY; Visco C; Tzankov A; Zou D; Qiu L; Montes-Moreno S; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Ai W; Ponzoni M; Ferreri AJ; Winter JN; Go RS; Piris MA; Møller MB; Wu L; Wang M; Ramos KS; Medeiros LJ; Young KH
Blood; 2013 May; 121(22):4529-40. PubMed ID: 23515929
[TBL] [Abstract][Full Text] [Related]
13. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
[TBL] [Abstract][Full Text] [Related]
14. Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.
Mohamed G; Talima S; Li L; Wei W; Rudzki Z; Allam RM; Simmons W; Tao Q; Murray PG
Pathol Oncol Res; 2019 Jul; 25(3):1223-1231. PubMed ID: 30739251
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
Chiappella A; Diop F; Agostinelli C; Novo M; Nassi L; Evangelista A; Ciccone G; Di Rocco A; Martelli M; Melle F; Moia R; Motta G; Righi S; Santambrogio E; Tucci A; Balzarotti M; Ladetto M; Pileri SA; Gaidano G; Vitolo U;
Br J Haematol; 2022 Mar; 196(5):1184-1193. PubMed ID: 34951009
[TBL] [Abstract][Full Text] [Related]
16. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
Xu-Monette ZY; Deng Q; Manyam GC; Tzankov A; Li L; Xia Y; Wang XX; Zou D; Visco C; Dybkær K; Li J; Zhang L; Liang H; Montes-Moreno S; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Wang SA; Miranda RN; Piris MA; Winter JN; Medeiros LJ; Li Y; Young KH
Clin Cancer Res; 2016 Jul; 22(14):3593-605. PubMed ID: 26927665
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations and rituximab-CHOP.
Gisselbrecht C
Blood; 2012 Nov; 120(19):3867-9. PubMed ID: 23144158
[No Abstract] [Full Text] [Related]
19. Double-hit Signature with
Song JY; Perry AM; Herrera AF; Chen L; Skrabek P; Nasr MR; Ottesen RA; Nikowitz J; Bedell V; Murata-Collins J; Li Y; McCarthy C; Pillai R; Wang J; Wu X; Zain J; Popplewell L; Kwak LW; Nademanee AP; Niland JC; Scott DW; Gong Q; Chan WC; Weisenburger DD
Clin Cancer Res; 2021 Mar; 27(6):1671-1680. PubMed ID: 33414134
[TBL] [Abstract][Full Text] [Related]
20. TP53 and outcome in DLBCL: not only the coding region.
Jardin F; Coiffier B
Blood; 2013 May; 121(22):4433-4. PubMed ID: 23723442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]